Brokers Offer Predictions for Oculis Holding AG’s Q3 2024 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Investment analysts at Leerink Partnrs cut their Q3 2024 earnings estimates for Oculis in a research report issued on Wednesday, September 4th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.51) per share for the quarter, down from their prior forecast of ($0.39). The consensus estimate for Oculis’ current full-year earnings is ($2.19) per share. Leerink Partnrs also issued estimates for Oculis’ Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($2.12) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($2.65) EPS, FY2027 earnings at ($2.48) EPS and FY2028 earnings at ($0.53) EPS.

Several other research analysts also recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Tuesday, June 11th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Oculis in a research report on Wednesday, August 28th. Bank of America decreased their price objective on Oculis from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, June 11th. Finally, Robert W. Baird increased their price objective on shares of Oculis from $35.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $30.17.

Oculis Stock Performance

Shares of OCS opened at $12.01 on Monday. Oculis has a one year low of $9.05 and a one year high of $14.47. The firm has a market capitalization of $486.41 million, a P/E ratio of -6.75 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. The business has a fifty day moving average of $11.71 and a 200 day moving average of $11.84.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.